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The emergence of recombinant therapeutic proteins whose indications range from 
anti-cancer to rheumatoid arthritis treatments represented a significant revolution for 
modern pharmaceutical industry. When introduced into patients, the immunogenicity, 
bioactivity, and serum half-life of the therapeutic proteins are greatly impacted by their 
glycosylation patterns, especially the antennarity of the N-glycan and the level of 
terminal sialylation. To introduce α2,6-sialic acids and elevate overall sialylation level, a 
human α2,6-sialytransferase (ST6GAL1) was expressed in Chinese hamster ovary (CHO-
K1) cells which produce recombinant human erythropoietin (EPO). In addition, both 
UDP-N-acetylglucosamine: α-1,3-D-mannoside β1,4-N-acetylglucosaminyltransferase 
(GNTIV/Mgat4 ) and UDP-N-acetylglucosamine:α-1,6-D-mannoside β1,6-N-
acetylglucosaminyltransferase (GNTV/Mgat5) were further incorporated into the CHO-
K1 cell line expressing EPO and ST6GAL1.  
Firstly, stable clones of CHO-K1 cells expressing glycosyltransferases were 
established. CHO-K1 cell line expressing recombinant EPO (ChEPO) was transfected 
with ST6GAL1. The stable pool was created by drug selection and stable clone (ChEPO-
S) was picked by lectin blot. Similarly, GNTIV and GNTV were simultaneously 
transfected into ChEPO-S cells. Once the stable pool was constructed, the stable clone 
(ChEPO-SG) was selected using western blot and lectin blot analysis.  
The second goal of this thesis was to examine the expression and function of 
ST6GAL1, GNTIV and GNTV in ChEPO-S and ChEPO-SG cell lines. The expression of 
the transfected genes at both transcription and translation levels were confirmed by RT-
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PCR and western blot, respectively. The impact of these glycosyltransferases on the level 
of terminal sialylation as well as the degree of branching of intracellular proteins and 
purified EPO from the various CHO cell lines was evaluated. Lectin blot analysis 
indicated that transfection of ST6GAL1 indeed introduced α2,6-sialic acids and increased 
overall sialylation level. Higher extent of β1,4 and β1,6 branching at the N-glycan 
trimannosyl core was also observed. HPLC analysis quantified the sialic acid content of 
recombinant human EPO purified from each cell line. Results demonstrated that 
recombinant human EPO produced by ChEPO-S and ChEPO-SG cells respectively 
contained ~26% and ~45% more sialic acids compared to EPO from ChEPO cells. 
In this study, for the first time three glycosyltransferases, ST6GAL1, GNTIV and 
GNTV, were overexpressed in CHO-K1 cells in a simultaneous and coordinated manner. 
This strategy allows robust enhancement of the N-glycan complexity and terminal 
sialylation of recombinant therapeutic proteins produced by CHO cells. 
 
Advisor: Dr. Michael Betenbaugh 
Reader: Dr. Kevin Yarema  
 iv 
Acknowledgements  
I would first like to thank my advisor, Dr. Michael Betenbaugh, for accepting me 
into his lab when I was a sophomore and for allowing me to continue pursing my Master 
degree. My experience at the Betenbaugh Lab has been truly rewarding and fulfilling. 
Conducting scientific research has made me learn and grow so much, and completing my 
Master’s thesis will be one of my proudest accomplishments. I would like to thank Dr. 
Betenbaugh again for guiding me and inspiring me as both an undergraduate and 
graduate student. I sincerely appreciate everything he has made over the past several 
years. 
Secondly. I would like to express my gratitude to Dr. Bojiao Yin for and 
mentoring me during my study at the Betenbaugh Lab. She has taught and helped me 
immensely with excellent caring and patience on my glycoengineering research. I could 
not have been able to complete my thesis without her mentorship. 
Next, I would like to extend my thanks to the colleagues at the Betenbaugh Lab 
that have helped with my research and thesis. I would especially like to thank Andrew 
Chung, Qiong Wang, Mark Stuczynski, Coral Fung, Jeffery Chu, Joey Priola, and Kelly 
Heffner. Thank you for the help and friendship. 
Finally, I thank my parents and my boyfriend for all of their support during my 
undergraduate and graduate careers. Without their generous love and encouragement, I 
could not have made any of my achievements.  
  
 v 
Table of Contents 
Abstract .............................................................................................................................. ii 
Acknowledgements .......................................................................................................... iv 
List of Figures .................................................................................................................. vii 
List of Tables .................................................................................................................. viii 
Chapter 1: Introduction ................................................................................................... 1 
1.1 Protein Glycosylation and Sialylation ................................................................................ 1 
1.1.1 Complex N-glycan Branching .................................................................................... 2 
1.1.2 Sialylation ................................................................................................................... 4 
1.2 Importance of Glycosylation and Sialylation of Recombinant Proteins Produced in 
Chinese Hamster Ovary Cells .................................................................................................. 6 
1.3 Erythropoietin as a Model Protein for Glycoengineering Study ..................................... 6 
Chapter 2: Incorporation of ST6GAL1, GNTIV and GNTV into CHO-K1 cells .... 10 
2.1 Enhancing the Glycosylation and Sialylation of Recombinant Glycoproteins ............ 10 
2.1.1 Overexpression of Sialylation Pathway Enzymes ........................................................ 10 
2.1.2 Overexpression of N-acetylglucosaminyltransferases ................................................. 11 
2.2 Previous Work ................................................................................................................... 12 
2.3 Materials and Methods ..................................................................................................... 13 
2.3.1 Cell Lines ..................................................................................................................... 13 
2.3.2 Transfection .................................................................................................................. 14 
2.3.3 Isolation of Single Clones by Limiting Dilution .......................................................... 14 
2.3.4 Reverse Transcription PCR .......................................................................................... 15 
2.3.5 Protein Purification ...................................................................................................... 15 
2.3.6 SDS-PADE ................................................................................................................... 16 
2.3.7 Western Blot ................................................................................................................. 16 
2.3.8 Lectin Blot .................................................................................................................... 17 
2.4 Results and Discussion ...................................................................................................... 18 
2.4.1 Selection of the Stable Clone of ChEPO-S .................................................................. 18 
2.4.2 Selection of the Stable Clone of ChEPO-SG ............................................................... 19 
2.4.3 Expression of ST6GAL1, GNTIV and GNTV on Transcription Level ....................... 23 
2.4.4 Expression of ST6GAL1, GNTIV and GNTV on Translation Level .......................... 24 
Chapter 3: Enhanced N-glycan Branching and Sialylation of Recombinant Human 
Erythropoietin ................................................................................................................. 26 
3.1 Glycoengineering for the Development of Biosimilars ................................................... 26 
3.2 Materials and Methods ..................................................................................................... 28 
3.2.1 Cell Lines ..................................................................................................................... 28 
3.2.2 Immunoaffinity Purification of EPO ............................................................................ 28 
3.2.3 SDS-PAGE ................................................................................................................... 28 
3.2.4 Western Blot ................................................................................................................. 28 
3.2.5 Lectin Blot .................................................................................................................... 29 
3.2.6 Sialic Acid Analysis by High Performance Liquid Chromatography .......................... 29 
3.3 Results and Discussion ...................................................................................................... 29 
3.3.1 Lectin Blot Analysis for Various Erythropoietin Producing Cell Lines ...................... 29 
3.3.2 Recombinant Erythropoietin Purified by Ni-NTA and Detected by Lectins ............... 31 
3.3.3 Sialic Acid Content of Recombinant Erythropoietin Determined by HPLC................ 33 
 vi 
Chapter 4: Conclusion .................................................................................................... 36 
Chapter 5: Future Work ................................................................................................ 39 
5.1 Mass Spectrometry to Analyze Recombinant Human EPO N-glycan Structures ....... 39 
5.2 Further Improvement of Sialylation by Nucleotide Sugar Precursor Feeding ............ 39 
5.3 Enhancement of Sialylation by Targeted Gene Silencing .............................................. 40 
References ........................................................................................................................ 42 
CV ..................................................................................................................................... 48 
 
vii 
List of Figures 
Figure 1. Pentasaccharide Core of N-glycans ..................................................................... 1 
Figure 2. Three main structure types of N-glycans ............................................................. 2 
Figure 3. N-glycosylation pathway for a therapeutic protein produced in CHO cell ......... 3 
Figure 4. Mammalian biosynthesis pathway for CMP-sialic acid ...................................... 5 
Figure 5. Two types of sialic acids commonly seen on glycoproteins produced in 
mammalian cells ................................................................................................................. 8 
Figure 6. Lectin blot with SNA of total protein from seven ChEPO-S stable clones....... 19 
Figure 7. Lectin blot analysis for ChEPO-SG stable clones ............................................. 21 
Figure 8. Anti-GNTIV western blot analysis for ChEPO-SG stable clones ..................... 22 
Figure 9. Anti-EPO western blot analysis for ChEPO-SG stable clones .......................... 22 
Figure 10. RT-PCR analysis for genes transfected into various CHO-k1 cell lines ......... 23 
Figure 11 Western blot analysis for transfected human glycosyltransferases .................. 25 
Figure 12. Lectin blot analysis for total intracellular protein from various CHO cell lines
........................................................................................................................................... 31 
Figure 13. Lectin blot analysis of recombinant human EPO purified from various cell 
lines ................................................................................................................................... 33 
Figure 14. HPLC chromatograms for sialic acid .............................................................. 34 
Figure 15. Sialic acid content of recombinant human EPO produced by ChEPO, ChEPO-
S and ChEPO-SG cell lines............................................................................................... 35 
 viii 
List of Tables 
Table 1. The forward and reverse primers used in RT-PCR analysis for the mRNA 
expression of EPO, ST6GAL1, GNTIV and GNTV ........................................................ 15 
Table 2. Primary and secondary antibodies used in western blot analysis for EPO, 
ST6GAL1, GNTIV and GNTV ........................................................................................ 17 








Chapter 1: Introduction 
 
1.1 Protein Glycosylation and Sialylation 
 Glycosylation of newly synthesized proteins is the most ubiquitous and common 
post-translational modification, which produces attachment of oligosaccharides to either 
asparagine (N-linked) or serine/threonine (O-linked) through covalent linkages [1, 2]. 
According to the SwissProt protein database, more than 50% of eukaryotic proteins are 
glycoproteins, with 90% of them are expected to contain N-glycosylation [3]. N-
glycosylation is critical for glycoproteins of therapeutic importance, as it modulates the 
pharmacokinetics, immunogenicity, bioactivity, solubility, stability, protein folding and 
cellular processing [2, 4, 5].  
 N-glycans arise when sugar residues are added to the nascent protein in the 
endoplasmic reticulum (ER), and are further trimmed and processed in Golgi complex as 
the glycoproteins mature [6]. All N-glycans contain a saccharide core unit, Manα1–
6(Manα1–3)Manβ1–4GlcNAcβ1–4GlcNAcβ1-Asn-X-Ser/Thr (See Figure 1) [7]. 
 
Figure 1. Pentasaccharide core of N-glycans. A conservative set of five- 
saccharide core unit, Manα1–6(Manα1–3)Manβ1–4GlcNAcβ1–4GlcNAcβ1- 
Asn-X-Ser/Thr, can be found in all N-glycans. 
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1.1.1 Complex N-glycan Branching 
The structures of N-glycans can be categorized into three types: (1) 
oligomannose, (2) complex, and (3) hybrid. The oligomannose type only contains 
mannose residues that are attached to the core structure (See Figure 2a). In the complex 
type, N-acetylglucosaminyltransferases (GlcNAcTs) originate two to four antennae from 
the α1,3 and α1,6 mannose residues of the core. A typical antenna in complex N-glycans 
consists of a galactose (Gal) β1,4-linked to a β1,2-GlcNAc, followed by a terminal N-
acetylneuraminic acid (NeuNAc), or sialic acid (See Figure 2b). Finally, the hybrid type 
features characteristics of both oligomannose and complex type N-glycans, in which only 
mannose residues are connected to the Manα1–6 arm of the core, and one or two 
antennae are initiated from the Manα1–3 arm (See Figure 2c) [7, 8]. 
 
             
Figure 2. Three main structure types of N-glycans. (a) Oligomannose  
(b) Complex (c) Hybrid [7].   
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N-glycans exhibit complex-type structures in mammalian cells and the 
biosynthesis process involves a complicated glycosylation network of enzymes, including 
glycosidases and glycosyltransferases. An example N-glycosylation of a glycoprotein 
expressed in Chinese Hamster Ovary (CHO) cells is represented in Figure 3. Once the 
glycoprotein is translocated into the Golgi apparatus and trimmed by Golgi α-
mannosidases (α MAN-I and α MAN-II), it is modified by a variety of N-
acetylglucosaminyltransferases (GNTI to GNTVI or Mgat1 to Mgat 5) [9, 10]. GNTI and 
GNTII attach GlcNAc residues onto each the α1,3 and α1,6 mannose branch, creating the 
classic complex biantennary structure. Meanwhile, the N-glycan structure can be further 
remolded by additional N-acetylglucosaminyltransferases to form more complex 
structures. In particular, GNTIV (UDP-N-acetylglycosamine:α-1,3-D-mannoside β-1,4-
N-acetylglcosaminyltransferase, EC 2.4.1.145) and GNTV (UDP-N-
acetylglycosamine:α-1,6-D-mannoside β-1,6-N-acetylglcosaminyltransferase, EC 
2.4.1.155) are in charge of generating tri-antennary and tetra-antennary structures.  
 
Figure 3. N-glycosylation pathway for a therapeutic protein produced in CHO cell [11]. 
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The complex N-glycan branched structures regulate many important biological 
functions, such as cancer metastasis, T-cell activation and autoimmunity [12, 13]. The N-
glycan branching of a glycoprotein affects not only the molecular weight of the protein, 
but also the clearance rate of the protein by glomeruli of kidneys [14]. Furthermore, the 
number of N-glycan branches directly decides the amount of sites available for further N-
glycosylation processing to create various glycoforms. In particular, a galactose (Gal) 
residue can be added to the GlcNAc residues, and subsequently the sugar chain can be 
elongated by addition of GlcNAc residues to form lactosamine repeats (Galβ1,4-GlcNAc) 
[15]. On the other hand, a sialic acid residue can also be transferred to the terminal 
positions of galactosylated oligosaccharide chains [16, 17].  
1.1.2 Sialylation 
In mammalian cells, sialic acids capped N-glycans are constituents of various 
glycoproteins of biological importance, such as lectins, antibodies (e.g. IgG) and 
luteinizing hormones [18]. Sialic acid is a large family of negatively charged acidic 9-
carbon monosaccharide, with N-acetylneuraminic acid (NeuNAc or NANA) as the most 
common form [19]. Masking the terminal Gal of the N-glycan chain to avoid 
endocytosis-mediated capture by receptors of the hepatocytes, sialic acids prevent the fast 
removal of the glycoprotein from circulation [20]. Previous studies have proven that 
hypersialylation indeed enhances the overall efficacy and circulatory half-life of many 
important therapeutic glycoproteins, including but not limited to asparaginase, leptin and 
erythropoietin [21-25].  
For the occurrence of sialylation, a cytidine monophospho-sialic acid (CMP-SA) 
is formed in the nucleus by the conversion of sialic acid by CMP-SA synthetase, 
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transported to the Golgi apparatus by a CMP-SA transporter, and attached to the acceptor 
oligosaccharide by the sialyltransferase (See Figure 4). 
 
 
                          Figure 4. Mammalian biosynthesis pathway for CMP-sialic acid. The enzymes  
                          involved in the process are indicated: GNE, NANS, NANP, CMAS, CMP-Neu5Ac  
                          transporter (CST), and sialyltransferase (ST) [26]. 
 
To maximize the level of sialylation of a glycoprotein in mammalian cells, two 
opposing processes need to be considered. Firstly, a sialic acid can be converted to a 
CMP-SA substrate and then added to the terminal N-glycan by the sialyltransferase. 
Meanwhile, a terminal sialic acid can also be removed by sialidase cleavage [11]. There 
are two major families of sialytransferases in mammalian cells: ST3GAL and ST6GAL 
families. Specifically, ST6GAL1 from the ST6GAL family transfers the sialic acid to the 
terminal Gal, creating an α-2,6 linkage, whereas ST3GAL3, ST3GAL4, and ST3GAL6 
from the ST3GAL family create α-2,3 linked sialylation [27].  
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1.2 Importance of Glycosylation and Sialylation of Recombinant Proteins Produced 
in Chinese Hamster Ovary Cells 
Nowadays, intensive academic and industrial research focus on biopharmaceutical 
proteins such as monoclonal antibodies, growth factors, hormones, cytokines, and fusion 
proteins [28]. These proteins have a broad range of indications from anti-cancer to 
rheumatoid arthritis treatments, showing great clinical and economic importance. Over 60% 
of the biopharmaceutical proteins are glycoproteins, and they can undergo a series host-
generated responses after taken by a patient [29]. For example, if the glycoprotein is 
orally administered, it can get denatured by the acid in the gastrointestinal tract. If it is 
parenterally administered, it can be recognized and removed by renal and hepatic 
enzymes. In addition, a glycoprotein can be considered as antigenic, and thus can trigger 
the stimulation of an immune response [18]. Hence, glycoengineering of 
biopharmaceutical proteins with reduced antigenicity and improved efficacy is of great 
need and importance. 
Currently, the majority of biopharmaceutical glycoproteins is produced in 
mammalian cell expression systems [30]. Although other expression systems, such as 
yeast, insect and plants, have also been utilized to produce recombinant proteins, 
mammalian expression platform is principally chosen mainly due to its capability to 
produce glycosylation patterns similar to human [31]. Mammalian cells frequently used 
in biopharmaceutical industry include Chinese hamster ovary (CHO), baby hamster 
kidney (BHK-21), murine myeloma (NS0 and Sp2/0) and human cells [11]. Among them, 
about 70% of recombinant therapeutic proteins are produced in CHO cells because they 
can grow in suspension and chemically defined medium, reach a high-density culture, be 
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easily transfected, perform post-translational modifications including glycosylation, and 
normally do not cause immunogenic responses or safety issues compared to murine 
myeloma and human cells [11, 32, 33]. However, glycosylation patterns found in CHO 
cells have discrepancies compared to those in human cells, especially at the level of 
terminal sialylation. For example, N-glycans on native proteins expressed in human cells 
contain a mixture of both α2,3- and α2,6-linked sialic acids, but recombinant 
glycoproteins produced in most CHO cells usually exclusively display α2,3-linked 
sialylation due to their lack of the expression of α2,6-sialytransferases [34-36]. Moreover, 
on N-glycans of glycoproteins expressed in CHO cells, a type of non-human epitope, N-
glycolnylneuraminic acid (Neu5Gc or NGNA), can be found (See Figure 5). As a 
derivative of Neu5Ac, Neu5Gc is a major sialic acid that can be found in a variety of 
mammalian cells. However, human cells do not contain Neu5Gc because they lack CMP-
Neu5Ac hydroxylases which catalyze the conversion of Neu5Ac into Neu5Gc [37]. 
Therefore, the existence of Neu5Gc on therapeutic glycoproteins can potentially lead to 
immunogenic responses and compromised efficacies in patients [38]. The amount of 
Neu5Gc varies from protein to protein. For instance, fetuin contains about 7% of Neu5Gc 
of total sialic acids and causes immunogenic responses. On the contrary, there is only a 
low level of Neu5Gc (around 1% of total sialic acids) present on recombinant 




           Figure 5. Two types of sialic acids commonly seen on glycoproteins produced in  
           mammalian cells. N-acetylneuraminic acid (Neu5Ac) (left). N-glycolnylneuraminic  
           acid (Neu5Gc) (right).  
 
1.3 Erythropoietin as a Model Protein for Glycoengineering Study 
As previously mentioned, the branches of the complex N-glycan and terminal 
sialic acids affect the stability, bioactivity and efficacy of therapeutic glycoproteins. Thus, 
it is desirable to engineer the CHO cell line in order to produce recombinant 
glycoproteins with more N-glycan branches and higher level of sialylation. 
Erythropoietin (EPO) serves as a model glycoprotein for this glycoengineering study 
because it is heavily glycosylated and it exhibits considerable molecular heterogeneity.  
Human EPO is a hormone mainly synthesized in the kidney that functions to 
regulate red blood cell maturation and production [40]. Recombinant human EPO is an 
important therapeutic protein for the treatment of anemia associated with severe renal 
damage, HIV infection, and cancer chemotherapy [41, 42]. Consisting of a polypeptide of 
165 amino acids and a high content of glycans, human EPO has an overall molecular 
weight of 34 – 39 kDa [42]. The glycoprotein contains 3 N-glycosylation sites (Asn 24, 
Asn 38, and Asn 83) and 1 O-glycosylation site (Serine 126) [43]. The glycan chains 
comprise about 40% of the molecular weight of human EPO and mostly cover the surface 
of the protein [44]. Each of the three N-glycan chains of human EPO has the potential for 
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different branching ranging from 2 to 4, and each branch contains a potential terminal 
sialic acid [44].  
Besides EPO, several other glycoproteins, such as human interferon- γ (INF- γ) 





Chapter 2: Incorporation of ST6GAL1, GNTIV and GNTV 
into CHO-K1 Cells 
 
2.1 Enhancing the Glycosylation and Sialylation of Recombinant Glycoproteins 
As mentioned in Chapter 1, it is highly desirable to improve the extent of 
glycosylation, especially at the level of terminal sialylation, of recombinant therapeutic 
glycoproteins produced by CHO cells, because it can enhance the stability, bioactivity 
and efficacy of the proteins. Many approaches can be utilized to influence the level of 
glycosylation, including alteration of the activity of glycosyltransferases for sugar residue 
transfer, the action of glycosidases on the glycan degradation, and the amount of 
nucleotide sugar substrate [30]. This glycoengineering study focuses on increasing the 
availability and activity of glycosyltransferases in order to improve the N-glycan 
structures. 
2.1.1 Overexpression of Sialylation Pathway Enzyme 
Due to the particular importance of sialic acids on therapeutic glycoproteins, it is 
beneficial to create hypersialylation by engineering the sialytransferases. As noted 
previously, unlike human glycoproteins that contain a mixture of both α2,3- and α2,6-
linked sialylation, recombinant glycoproteins produced by CHO cells bear sialic acids 
with exclusively α2,3-linkages. Therefore, overexpression of heterologous α2,6-
sialyltransferase becomes a conducive method. Bragonzi et al. successfully established a 
CHO cell line as a universal host for glycoprotein production by stably expressing the 
α2,6-sialyltransferase gene. They observed that the transgene was stably integrated into 
the CHO cell genome, and the recombinant sialylatransferase was correctly localized in 
the Golgi. The transfected CHO cell line showed similar growth characteristics compared 
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to the wild type CHO cells. In addition, they expressed IFN-γ in their host CHO cell line, 
and found that the purified IFN-γ carried 40.4% α2,6- and 59.6% α2,3-linked sialic acid 
residues, and that the glycoprotein exhibited enhanced pharmacokinetics in clearance 
studies [45]. Jassal et al. transfected a rat α2,6-sialyltransferase gene into the CHO-K1 
cell line expressing IgG3 antibody, and observed an enhanced overall sialylation level of 
IgG-Fc-linked carbohydrate. The ratio of α2,6- to α2,3- sialic acid also increased from 
0.0:1.0 to 0.9:1.0 [46]. Several other studies have also shown that overexpression of α2,6-
sialytransferase into CHO cells introduced the α2,6-linked sialylation, elevated the level 
of terminal sialic acids, and enhanced the bioactivity of the recombinant glycoprotein [47, 
48]. 
2.1.2 Overexpression of N-acetylglucosaminyltransferases 
Complex N-glycan may include bi-, tri-, and tetra-antennary structures. As 
mentioned in Chapter 1.1.1, GNTIV and GNTV are responsible for the tri- and tetra-
antennary structures. Fukuta et al. transfected genes encoding GNTIV and GNTV 
enzymes into human IFN-γ producing CHO cells, and indeed increased the percentages 
of tri- and tetra-antennary structures of total N-glycans. Without transfection, IFN-γ 
produced by CHO cells mainly exhibited the classic biantennary structure. When GNTIV 
was overexpressed, triantennary N-glycan with β1,4 branch at the trimannosyl core 
increased up to 66.9% of the total sugar chains. Transfection of GNTV increased the 
triantennary N-glycan with β1,6 branch up to 55.7%. When both GNTIV and GNTV 
were overexpressed simultaneously, the tetraantennay N-glycosylation pattern was 
elevated to 56.2% [48]. 
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2.2 Previous Work 
Our study investigated the influence of several glycosyltransferases overexpressed 
in CHO-K1 cells on the level of sialylation and N-glycan branching of the recombinant 
human EPO. Due to the length of the study, some work has been done prior to this thesis. 
Previously, the ChEPO stable cell line has been established and the effects of each 
ST6GAL1, GNTIV and GNTV have been characterized. The recombinant human EPO 
was transfected into CHO-K1 cells, and by drug selection, the stable pool was 
constructed. The single clone with the highest EPO expression level was selected using 
indirect ELISA and additionally confirmed using western blot analysis. The stable clone 
was termed ChEPO and utilized as the host cell line for further glycoengineering 
experiments in our study. 
In addition, each of ST6GAL1, GNTIV and GNTV has been transiently 
transfected into the ChEPO cell line in order to get some preliminary results on how the 
overexpression of these glycosyltransferases could affect the production of recombinant 
human EPO as well as the pattern of protein N-glycosylation. Results showed that co-
expression of either ST6GAL1 or GNTIV with EPO did not influence the expression 
level of EPO. In contrast, when GNTV was transfected into ChEPO cells, a decreased 
production of EPO was observed. Using the lectin blot analysis, it was verified that 
overexpression of ST6GAL1 and GNTV significantly increased the level of α2,6-linked 
sialylation and β1,6-linked GlcNAc in both the total protein and the purified EPO 
produced by ChEPO cells. 
Therefore, in this thesis, further glycoengineering work will be continued. Firstly, 
ST6GAL1 will get transfected into the ChEPO cell line, and stable pools will be selected 
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with drugs. Limiting dilution will be performed to generate single clones, and these 
single clones will be screened for EPO production as well as the respective N-
glycosylation patterns using western blot and lectin blot analysis. The selected stable 
clone will be termed ChEPO-S. Next, ST6GAL1, GNTIV and GNTV will be 
simultaneously overexpressed in the ChEPO cell line, and the stable clone will be picked 
in a similar manner and named ChEPO-SG. With the establishment of the wild-type 
CHO-K1 (WT), ChEPO, ChEPO-S and ChEPO-SG cell lines, we will examine the 
expression of recombinant human EPO, ST6GAL1, GNTIV and GNTV in each cell line 
on both mRNA and protein level using RT-PCR and western blot analysis, respectively. 
Following confirmation of the functions of transfected glycosyltransferases will be 
carried out by lectin blot analysis of total protein and purified EPO from each cell line. In 
addition, HPLC analysis will be conducted to quantify the sialic acid content of purified 
EPO produced in each CHO cell line. 
 
2.3 Materials and Methods 
2.3.1 Cell Lines 
Adherent CHO-K1 cells (Thermo Fisher Scientific) were grown in 100mm TC-
treated culture dishes (Corning) in F-12K medium supplemented with 10% fetal bovine 
serum (FBS) (Thermo Fisher Scientific). Cells were maintained at 37oC and 5% CO2 in a 
Series 8000 – Direct Heat and Water Jacket CO2 incubator (Thermo Fisher Scientific). 
Every two to four days, when cells reached about 70 – 80% confluent, they were 




The ST6GAL1, GNTIV and GNTV constructs were transfected into EPO 
producing CHO-K1 cells (ChEPO) using Lipofectamine 2000 reagent (Life Technologies) 
in OptiMEM Reduced Serum Media (Life Technologies).  ChEPO cells were seeded onto 
a 6-well clear TC-treated cell culture plate (Corning) at appropriate densities one day in 
advance of the transfection. The ChEPO cells were then incubated in the OptiMEM 
medium with Lipofectamine 2000 reagent and plasmid DNA complex for 24 hours. 
Transfected stable pools were acquired by drug selection using blasticidin (EPO-S) and 
zeocin (EPO-SG).  
2.3.3 Isolation of Single Clones by Limiting Dilution 
ChEPO cells transfected with ST6GAL1, GNTIV and GNTV were stained with 
Trypan Blue (Sigma-Aldrich) and counted using a hemocytometer. The cells were 
subjected to serial dilutions to a concentration of 1000 cells/ml. Then single clones were 
established by further diluting and seeding 0.7 cell/well in 96-well clear TC-treated cell 
culture plates (Corning). 2ml of culture medium with appropriate concentrations of 
selection drugs were added to each well. After incubation for 5 to 7 days at 37oC and 5% 
CO2, plates were screened for single clones under the microscope. Two additional days 
later, plates were checked again to make sure no secondary colonies had grown. Several 
single clones were randomly picked, passaged to and expanded in 24-well clear TC-
treated cell culture plates (Corning). Selection drugs were still added to maintain the 




2.3.4 Reverse Transcription PCR 
Total RNA was purified from each wild-type CHO-K1, ChEPO, ChEPO-S and 
ChEPO-SG cells using the RNeasy Mini Kit (Qiagen), according to the manufacturer 
protocols. To investigate the corresponding mRNA expression level of the transfected 
human EPO, ST6GAL1, GNTIV and GNTV genes, 1μg of total RNA from each cell line 
was taken and used as the template for RT-PCR. PCR primers for each gene are outlined 
in Table 1. The PCR products were further subjected to electrophoresis on a 1% agarose 
gel at 60V for 50min, and then visualized by ethidium bromide staining.  
Gene Primer Direction Primer Sequence 
EPO 
Forward 5’-atgggcgtgcacgagtgtc-3’ 
Reverse 5’- tctatcgccggtccggcaa-3’ 
ST6GAL1 




Reverse 5’- tttgctttgttctccatcttac-3’ 
GNTV 
Forward 5’- gttgtttgttggacttgggtt-3’ 
Reverse 5’- acttcagcatgtccttgtcc-3’ 
Table 1. The forward and reverse primers used in RT-PCR analysis for the mRNA expression of  
EPO, ST6GAL1, GNTIV and GNTV. 
 
2.3.5 Protein Purification 
The wild-type CHO-K1, ChEPO, ChEPO-S and ChEPO-SG cell lines were each 
cultured in 100mm culture dishes in F-12K medium supplemented with 10% FBS. To 
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obtain the total protein lysate, when cells reached 90% confluent, medium was removed, 
and cells were lysed with RIPA buffer followed by brief sonication. 
The recombinant human EPO was purified from each cell line using the 
MagneHis protein purification system (Promega) according to the manufacturer’s 
instruction for purification of polyhistidine-tagged, secreted proteins from cultured 
mammalian cells. The only modification made in this study was that 40μl of MagneHis 
Ni-particles were added to 1ml of culture supernatant. 
2.3.6 SDS-PAGE 
Protein concentrations of purified EPO samples were measured using the BCA 
Assay (Thermo Scientific) prior to the SDS-PAGE.  Aliquots of purified EPO were 
stained with 5x SDS sample buffer supplemented with 2-mercaptoethanol, and then 
denatured by boiling at 95°C for 5 minutes. Samples were loaded onto 10% Mini-
PROTEAN polyacrylamide gels (BIO-RAD), and proteins were separated at a constant 
voltage of 180V for 45 minutes at room temperature.   
2.3.7 Western Blot 
After SDS-PAGE, proteins were transferred from the polyacrylamide gel to the 
Immun-Blot polyvinylidene difluoride (PVDF) membrane (BIO-RAD) by blotting for 60 
minutes at a constant 100V.  The PVDF membrane was treated prior to protein transfer 
by soaking it in 100% methanol, rinsing with deionized (DI) water for one minute, and 
finally submerging it in the transfer buffer.  
For western blot, the membrane was blocked at room temperature with 5% milk 
in PBST (phosphate-buffered saline with 0.5% Tween 20) for an hour, and then 
incubated in primary antibodies diluted in 5% milk for another hour on a shaker (See 
 17 
Table 2). The membrane was then washed three times by PBST, 20min each time, and 
incubated with HRP-conjugated secondary IgG antibody (Cell Signaling Technology) for 
an extra hour. The membrane was thoroughly washed with PBST for three times again.  
 
Protein Primary Antibody Secondary Antibody 
EPO Mouse anti-EPO (Abcam) Anti-mouse IgG 
ST6GAL1 Mouse anti-ST6 (Sigma) Anti-mouse IgG 
GNTIV Rabbit anti-Mgat4 (Abcam) Anti-rabbit IgG 
GNTV Mouse anti-Mgat5 (Abcam) Anti-mouse IgG 
              Table 2. Primary and secondary antibodies used in western blot analysis for EPO,  
              ST6GAL1, GNTIV and GNTV. 
 
Finally, the membrane was visualized with chemiluminescent detection of the 
secondary antibody using the Lumina Forte Western HRP Substrate (Milipore) in a 
Molecular Imager ChemiDoc XRS (BIO-RAD) with Quantity One Software (BIO-RAD). 
The densitometry analysis was performed using ImageJ software (NIH) according to the 
blot analysis protocol. 
2.3.8 Lectin Blot 
For lection blot, after proteins were transferred to the PVDF membranes as 
previously described (See Chapter 2.3.7), the membranes were blocked in 1× Carbo-Free 
solution (Vector Labs) for one hour at room temperature. Next, membranes were 
incubated for another one hour at room temperature in Biotinylated Sambucus Nigra 
Lectin (SNA), Datura Stramonium Lectin (DSL), or Phaseolus Vulgaris  Leucoagglutinin 
(PHA-L) which were diluted by 1:5000 in 5 ml of  TBST (Tris-buffered saline with 0.5% 
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Tween 20). Then the membrane was washed thoroughly with TBST and continuously 
incubated in Avidin D, Horseradish Peroxidase (Av-HRP) diluted by 1:10000 in 5 ml of 
TBST. The membranes were again washed with TBST to eliminate unspecific binding 
and developed as previously described (See Chapter 2.3.7). 
 
2.4 Results and Discussion 
2.4.1 Selection of the Stable Clone of ChEPO-S  
ST6GAL1 (PubMed Gene ID: 6480) cDNA (OriGene) which encodes the α2,6-
sialyltransferase was subcloned into pEF6/V5-his TOPO TA. The plasmid DNA was 
transfected into ChEPO cells. To obtain the ChEPO-S stable pool, selection drugs were 
added to the cell culture medium. The transfected ChEPO cells kept undergoing selection 
process until the wild-type ChEPO cells reached less than 10% cell viability. After the 
establishment of the ChEPO-S stable pool, the cells were harvested and lysed. Equal 
amount of total intracellular protein from seven ChEPO-S single clones were subjected to 
SDS-PAGE and lectin blotting with SNA which reacts to the α2,6-sialic acid linkage (See 
Figure 6). The single clone with the highest reaction activity with SNA (Lane 6) was 




                   Figure 6. Lectin blot with SNA of total intracellular protein from seven ChEPO-S  
                   stable clones. M: Protein marker; control: total protein from ChEPO cells; 1-7: total  
                   intracellular protein from ChEPO-S stable clones. 
 
2.4.2 Selection of  the Stable Clone of ChEPO-SG 
To create the ChEPO-SG cell line, human GNTIV and GNTV were additionally 
transfected into the ChEPO-S cell line. Because human GNTIV and GNTV genes are 
naturally present in human cells, they were cloned by reverse-transcription PCR (RT-
PCR) from HEK 293 cells. Primer sequences used to capture GNTIV and GNTV are 







Gene Primer Direction Primer Sequence 
GNTIV 





     Table 3. Primers used in RT-PCR to clone GNTIV and GNTV from HEK 293 cells. 
 
Similar to the selection process of ChEPO-S stable clone, human GNTIV and 
GNTV cDNA were inserted into pBudCE4.1 through the NotI/XhoI and SalI/Xbal sites, 
respectively, with GNTIV under EF1α promoter and GNTV under CMV promoter. The 
DNA construct was transfected into ChEPO-S cells. To obtain the ChEPO-SG stable pool, 
selection drugs were added to the cell culture medium. The transfected ChEPO cells kept 
undergoing selection process until the ChEPO-S cells reached less than 10% cell viability. 
Once the ChEPO-SG stable pool was created, 23 single clones were randomly picked for 
cell line selection. Total intracellular protein was prepared from each of the 23 ChEPO-
SG clones, and subjected to SDS-PAGE and lectin blot with PHA-L. Of all the 23 clones, 
nine clones (Lane 3, 6, 7, 8, 9, 13, 14, 15 and 19) exhibited relatively higher binding 
activity with PHA-L, suggesting higher expression and function of GNTV (See Figure 7). 




                    Figure 7. Lectin blot analysis for ChEPO-SG stable clones. Total intracellular  
                    protein was each prepared from 23 ChEPO-SG stable clones and analyzed by lectin  
                    blot with PHA-L to detect the level of β1,6 branch at the trimannosyl core of N- 
                    linked carbohydrate.  
 
For the nine ChEPO-SG clones, GNTIV and EPO proteins were analyzed by 
SDS-PAGE and western blot. As the anti-GNTIV western blot depicted, five samples 
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(Lane 1, 2, 7, 8 and 9) had two bands, probably as a result of non-specific binding. The 
rest four samples (Lane 3, 4, 5 and 6) exhibited one single band, indicating the correct 
expression of GNTIV protein (Figure 8).  
 
                      Figure 8. Anti-GNTIV western blot analysis for ChEPO-SG stable clones.  
                      GNTIV protein was purified from nine ChEPO-SG cell lines and analyzed by  
                      anti-GNTIV western blot.  
 
On the other hand, as the anti-EPO western blot result illustrated, all nine clones 
successfully produced human EPO protein, but three of them (Lane 1, 4, 9) showed 
relatively higher expression (See Figure 9). Combined with the results of previous PHA-
L lectin blot and anti-GNTIV western blot, Clone 4 was chosen as the stable ChEPO-SG 
cell line, as it demonstrated great GNTV function, correct GNTIV expression, and high 
EPO production. 
 
                  Figure 9. Anti-EPO western blot analysis for ChEPO-SG stable clones.  
                  Recombinant human EPO protein was purified from nine ChEPO-SG cell lines  





2.4.3 Expression of ST6GAL1, GNTIV and GNTV on Transcription Level 
In order to examine the expression of transfected human EPO, ST6GAL1, 
GNTIV and GNTV at the mRNA level, RT-PCR analysis of wild-type CHO-K1, ChEPO, 
ChEPO-S and ChEPO-SG cell lines was carried out (Figure 10). Because no 
heterologous gene was transfected, wild-type CHO-K1 cell line (Lane 1) had no EPO, 
ST6GAL1, GNTIV or GNTV expression at the transcription level. ChEPO (Lane 2) only 
contained EPO, while ChEPO-S (Lane 3) contained both EPO and ST6GAL1 transcripts. 
Transfected with all EPO, ST6GAL1, GNTIV and GNTV genes, ChEPO-SG cell line 
(Lane 4) indeed showed all four corresponding mRNAs. In the RT-PCR analysis, actin 
was used as an internal control. 
 
                               Figure 10. RT-PCR analysis for genes transfected into various CHO-k1  
                               cell lines. Lane 1: Wild-type CHO-K1 cell (WT); Lane 2: ChEPO; Lane 3:  





2.4.4 Expression of ST6GAL1, GNTIV and GNTV on Translation Level 
Since the mRNA expression of ST6GAL1, GNTIV and GNTV were confirmed 
using RT-PCR, the protein expression needs to be assessed as well. Total intracellular 
protein was prepared from each WT, ChEPO, ChEPO-S and ChEPO-SG cell lines. 
ST6GAL1, GNTIV and GNTV were then separated by SDS-PAGE and detected by 
corresponding antibodies in western blot analysis (See Figure 11). Consistent with the 
RT-PCR result, expression of ST6GAL1 protein was only found in ChEPO-S (Lane 3) 
and ChEPO-SG (Lane 4) cell lines. Although ChEPO-SG (Lane 4) showed obviously 
strongest reaction activities to anti-GNTIV and anti-GNTV antibodies, background 
binding can be seen in all cell lines. It is because endogenous GNTIV and GNTV from 
CHO cells display a significantly high amino acid similarity (~90%) to their human 
versions, and they also react to the antibodies used in western blot. Still, ChEPO-SG 
(Lane 4) exhibited 1.3 and 3.3 times higher level of GNTIV and GNTV enzymes 
compared to WT (Lane 1).   
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                  Figure 11. Western blot analysis for transfected human glycosyltransferases. 
(a) Lane 1: Wild-type CHO-K1 cells (WT); Lane 2: ChEPO; Lane 3: ChEPO-S;  
Lane 4: ChEPO-SG. (b) The fold increase of the ST6GAL1, GNTIV and GNTV  
proteins in ChEPO, ChEPO-S and ChEPO-SG cell lines compared to those  
                  in WT cell line. Note: Because there was zero expression of ST6GAL1 in WT and  





Chapter 3: Enhanced N-glycan Branching and Sialylation of 
Recombinant Human Erythropoietin 
 
3.1 Glycoengineering for the Development of Biosimilars 
With the development of biotechnology, recombinant therapeutic proteins have 
become an important medical option for a variety of indications. Recently, patents for a 
number of recombinant therapeutic protein products on market have expired or about to 
expire, such as interferons, human growth hormone, and erythropoietin. Therefore, 
alternatives of these recombinant proteins, biosimilars, have been widely studied and 
developed [49]. Unlike small-molecule generics, biosimilars are not identical to the 
reference products because recombinant therapeutic proteins are very complex and 
require multifaceted development and manufacturing processes [50].  
In particular, glycosylation has an important role in the development of 
biosimilars for two reasons. Firstly, as mentioned previously in Chapter 1.2, 
glycosylation has a large influence on the stability, solubility, pharmacokinetics, 
bioactivity and immunogenicity of recombinant therapeutic proteins. Secondly, unlike 
DNA and proteins that can be synthesized based on gene or amino acid sequences, 
glycosylation is processed not according to template sequences but in a complex network 
involving a hundreds of enzymes and transporters, leading to variable glycan structures 
among different cell lines and even cell clones. Hence, glycoengineering is a critical part 
of the development of biosimilars in order to reproduce the glycosylation pattern of the 
reference products [51]. 
Nowadays, many biosimilar studies are focusing on the erythropoietin. Epoetin is 
recombinant human erythropoietin used to treat anemia in patients with chronic kidney 
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failure and cancer patients receiving chemotherapy. Epoetin is manufactured by Amgen, 
and this drug is marketed by Amgen under the trade name Epogen and by the subsidiary 
of Johnson & Johnson, Janssen Biotech, under the trade name Procrit. Currently, all 
biosimilar epoetin products in clinical trials have a highly similar amino acid sequence 
compared to the native human EPO, but they have different production cell lines, 
manufacturing processes, dosage regimens, routes of administration, and most 
importantly glycosylation patterns [52]. Thus, in spite of the same molecular mechanism 
of action, these products showed different pharmacologic and clinical properties from the 
innovator epoetin drug. Successful biosimilar epoetins must show a high level of 
glycosylation-based similarity to the reference product, Epogen. Some biosimilars 
currently licensed in Europe include Abseamed (Medice Arzneimitel Putter, Germany), 
Binocrit (Sandoz GmbH Kundl, Austria), and Epoetin alfa Hexal (Hexal Biotech, 
Germnay) [53]. 
Glycoengineering is essential for the development not only for the biosimilar 
epoetins, but also other biopharmaceuticals such as monoclonal antibodies. Although 
antibodies from the IgG class harbor only a single glycosylation site in the Fc region, and 
sometimes an additional site in the Fab region, the glycosylation is critical for the 
antibody-dependent cell-cytotoxicity (ADCC) and thus crucial for the efficacy of the 
drug [54]. Recently, a mogamulizumab with the trade name Poteligeo was approved in 
Japan as the first glycoengineered biosimilar antibody to reach the market [55]. Since 
glycosylation is of great importance for the development of biosimilars, it is beneficial to 
glycoengineer mammalian cell lines and thus create a novel and stable glycosylation 
profile. 
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3.2 Materials and Methods 
3.2.1 Cell Lines 
CHO-K1 cells were cultured as previously described in Chapter 2.3.1. 
3.2.2 Immunoaffinity Purification of EPO 
Before protein purification, wild-type CHO-K1, ChEPO, ChEPO-S and ChEPO-
SG cell lines were each cultured in 100mm culture dishes in 8ml F-12K medium 
supplemented with 10% FBS. When cells reached 90% confluent, culture medium was 
changed to 8ml OptiMEM. In order to purify the secreted EPO, the cell culture 
supernatants were collected, filtered through membranes with a pore size of 0.45 μm, and 
then concentrated five times by centrifugal ultrafiltration using Amicon Ultra-15 
Centrifugal Filters with a molecular weight cutoff (MWCO) of 10 kDa (Minipore).   
The concentrated samples were loaded onto a column consisting of Ni-
Nitrilotriacetic Acid (Ni-NTA) agarose matrix (Promega) to which His-tag has a high 
binding affinity. After loading, the column was thoroughly washed with PBS. The bound 
EPO was then eluted with PBS supplemented with 250 μM imidazole. The eluent 
fractions were immediately dialyzed with PBS and loaded to the Superdex 75 gel 
filtration column (GE life sciences).  To evaluate the purity of purified EPO, the eluted 
samples were subjected to 10% SDS-PAGE followed by Coomassie Blue staining. Rest 
of the protein samples were stored at -20oC. 
3.2.3 SDS-PAGE 
SDS-PAGE analysis was carried out as previously described in Chapter 2.3.6. 
3.2.4 Western Blot 
Western blot analysis was performed as previously described in Chapter 2.3.7. 
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3.2.5 Lectin Blot 
Western blot analysis was conducted as previously described in Chapter 2.3.8. 
3.2.6 Sialic Acid Analysis by High Performance Liquid Chromatography 
 The sialic acid content of purified EPO was measured by reverse-phase HPLC 
with fluorescence detection [56]. 400μl of 25mM sulfuric acid was added to 1μg purified 
EPO samples and the mixtures were heated at 80°C for 1h to hydrolyze the sialic acid. 
Then the samples were combined with 400μl of 7.0mM 1,2-Diamino-4,5-
methylenedioxybenzene dihydrochloride (MDB; Dojindo), and incubated at 60°C for 
2.5h so that the sialic acid turned into highly fluorescent derivatives. N-acetylneuraminic 
acid (Neu5Ac) was diluted from 50 to 1000 μg/ml as a standard. Next, the MDB-labeled 
sialic acids from EPO were analyzed by HPLC (1260 Infinity; Agilent Technologies). A 
reverse-phase column with a length of 150mm and a particle size of 2.7 μm was used for 
separation (Poroshell120-ED-C18; Agilent Technologies). Sialic acids elution was 
monitored by a fluorescent detector (G1316A, Agilent) with the excitation and emission 
wavelengths at 367 nm and 445 nm. 
3.3 Results and Discussion 
3.3.1 Lectin Blot Analysis for Various Erythropoietin Producing Cell Lines 
Previously, the expression of GNTIV and GNTV were confirmed at both the 
transcription and translation level (See Chapter 2.4.3 and 2.4.4). However, the functions 
of human GNTIV and GNTV in CHO cells still need to be evaluated. Therefore, lectin 
blot was performed on the total intracellular protein prepared from WT, ChEPO, ChEPO-
S and ChEPO-SG cells lines. Biotinylated lectins were utilized to detect specific glycan 
structures: SNA reacts specifically to the α2,6 sialic acid, PHA-L binds to the β1,6 branch 
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at the trimannosyl core of N-linked carbohydrate (GlcNAcβ1-6 Manα1-6 Manβ-), and 
DSL reacts to the β1,4 branch at the trimannosyl core of N-linked carbohydrate [57].  
ChEPO-S cell line showed a significantly higher amount of α2,6 sialic acid 
compared to WT and ChEPO cell lines, but ChEPO-SG had even higher content than 
ChEPO-S. Densitometry analysis of the lectin blot indicated that the α2,6-sialylation 
level in ChEPO-S and ChEPO-SG cell lines are 2.4 and 2.6 times higher than the WT cell 
line, respectively. In spite of the background binding of PHA-L and DSL in WT, ChEPO 
and ChEPO-S cell lines, ChEPO-SG exhibited a remarkably increased binding activities, 
and densitometry analysis showed that compared to WT cell line, ChEPO-SG had 1.9- 
and 4.6-fold elevation of β1,6- and β1,4- branched N-glycan levels (See Figure 12). 
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Figure 12. Lectin blot analysis for total intracellular protein from various CHO cell lines. (a) Total 
cellular protein was analyses by lectin blot with SNA (left), PHA (middle), DSL (right). 1: WT; 2: ChEPO; 
3: ChEPO-S; 4: ChEPO-SG. Similar amount of total protein was loaded based on Coomassie blue staining. 
(b) The fold increase of the reaction activities to SNA, PHA and DSL of total proteins in ChEPO, ChEPO-
S and ChEPO-SG cell lines compared to those in WT cell line. 
 
 
3.3.2 Recombinant Erythropoietin Purified by Ni-NTA and Detected by Lectins  
To investigate the impact of ST6Gal1, GNTIV and GNTV on the model 
glycoprotein EPO, the same amount of purified recombinant human EPO from each 
ChEPO, ChEPO-S and ChEPO-SG cell lines were subjected to SDS-PAGE and lectin 
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blot analysis. During the SDS-PAGE, recombinant EPO purified from ChEPO and 
ChEPO-S cell lines showed similar migration rates, but recombinant EPO from ChEPO-
SG migrated much slower, which suggests that EPO produced in ChEPO-SG had a larger 
molecular weight compared to recombinant EPO from ChEPO and ChEPO-S cell lines. 
The increase of EPO size might be the result of the expansion of N-glycans due the 
expression of transferases, GNTIV and GNTV.  
 Next, lectin blot analysis with each SNA, PHA-L and DSL on recombinant 
human EPO was carried out. In contrast to recombinant human EPO produced in ChEPO 
cell line which showed no binding activity to SNA, EPO purified from ChEPO-S and 
ChEPO-SG had a significant binding reaction, proving a notable increase in α2,6-
sialylation. Without transfection of GNTIV and GNTV, ChEPO-S cell line indeed 
showed similar binding activity to PHA-L and DSL with ChEPO. Recombinant EPO 
produced by the ChEPO-SG cell line revealed a 2.5- and 2.7-fold higher binding activity 
to PHA-L and DSL compared to EPO from ChEPO and ChEPO-S cells, indicating an 
increased amount of β1,4- and β1,6- branched glycans (See Figure 13). 
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                 Figure 13. Lectin blot analysis of recombinant human EPO purified from various cell  
                 lines. (a) EPO was purified from each cell line with Ni-NTA affinity chromatography and  
                 detected by lectins: SNA, PHA and DSL. Western blot of similar amount of recombinant  
                 human EPO purified from each cell line was used as the control. 1: Wild-type CHO-K1  
                 cells (WT); Lane 2: ChEPO; Lane 3: ChEPO-S; 4: ChEPO-SG. (b) The fold increase of  
                 reaction activities toward SNA, PHA and DSL of recombinant human EPO purified from        
                 ChEPO, ChEPO-S and ChEPO-SG compared to ChEPO cell line. 
 
3.3.3 Sialic Acid Content of Recombinant Erythropoietin Determined by HPLC  
In order to investigate the effects of transfected ST6GAL1, GNTIV and GNTV on 
the sialylation level of recombinant human EPO produced in CHO-K1 cells, sialic acids 
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were released from purified recombinant EPO, derivatized with the fluorescent MDB, 
and then separated on a reverse-phase C18 column. Serial concentrations of sialic acid 
standards were measured first to serve as a reference of peak time and sialic acid 
concentration. The recombinant human EPO sialic acid samples from each cell line were 
subjected to HPLC analysis. The main peak which showed at the same time as the 





Figure 14. HPLC chromatograms for sialic acid. 50 – 1000 μg of sialic acid standard was serially     
injected. Only 800μg is shown here as a reference. The peak formed at 4.8 min (top). Sialic acid on  
recombinant human EPO produced by each ChEPO, ChEPO-S and ChEPO-SG was measured. The  
sialic acid content of 1 μg of EPO from ChEPO-SG cells is shown here. The major peak also formed  
at 4.8min, corresponding to the standard (below). 
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HPLC analysis for recombinant human EPO sialylation was performed several 
times, and the average sialic acid content on EPO produced by each cell line is shown in 
Figure 15. Compared to recombinant human EPO purified from ChEPO cell line into 
which no glycosyltransferases were transfected, EPO sialic acid contents from ChEPO-S 
and ChEPO-SG cell lines increased ~26% and ~45%, respectively.  
 
                             Figure 15. Sialic acid content of recombinant human EPO produced by ChEPO,  
                             ChEPO-S and ChEPO-SG cell lines. Sialic acid content of EPO was determined  








Chapter 4: Conclusion 
Recombinant biopharmaceutical proteins have revolutionized the treatment of 
many diseases and have become the most significant and profitable segment of the 
overall pharmaceutical industry. For these proteins, glycosylation plays an important role 
in influencing their stability, solubility, pharmacokinetics, bioactivity and 
immunogenicity [6]. Therefore, to ensure the quality of the recombinant therapeutic 
glycoproteins, glycoengineering has become an essential part of drug development 
process for both new molecules and biosimilars [58]. Major strategies to enhance the 
protein N-glycosylation, especially on the level of terminal sialylation, includes 
improving the availability and activity of glycosyltransferases, reducing the action of 
glycosidases, and providing cells more nucleotide sugar substrates [30].  
In this study, three glycosyltransferases, ST6GAL1, GNTIV and GNTV were 
transfected into human EPO producing CHO-K1 cells, creating three cell lines, ChEPO, 
ChEPO-S and ChEPO-SG. We investigated how these glycosyltransferases influence the 
level of α2,6-linked sialylation and N-glycan branching at the trimannosyl core of the 
recombinant human EPO.  
Firstly, a stable clone for each ChEPO-S and ChEPO-SG cell line was selected. 
ChEPO-S was obtained by transfecting ST6GAL1 gene into the ChEPO cell line, 
creating stable pool by drug selection, and picking the single clone the highest activity 
with SNA. Similarly, transfecting ChEPO-S with GNTIV and GNTV genes and 
establishing a stable pool by drug selection gave the ChEPO-SG cells. 23 single clones 
were randomly chosen and subsequently analyzed by lectin blot with PHA-L. 9 clones 
with high reaction activity were further evaluated by western blot with anti-GNTIV and 
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anti-EPO antibodies. Eventually, one clone with both correct GNTIV expression and high 
EPO production was chosen to be the ChEPO-SG stable line. 
The expression and function of ST6GAL1, GNTIV and GNTV in the ChEPO, 
ChEPO-S and ChEPO-SG stable clone were assessed. RT-PCR analysis confirmed the 
expression of the mRNA of corresponding glycosyltransferases in cells. Then, western 
blot verified the expression of glycosyltransferase proteins. To examine the effect of 
ST6GAL1, GNTIV and GNTV on protein glycosylation, lectin blot and HPLC analysis 
were carried out. Lectin blot with SNA, PHA-L and DSL for total protein lysate from 
each cell line indicated that compared to wild-type CHO-K1 and ChEPO cells, ChEPO-S 
and ChEPO-SG had significantly higher intracellular α2,6-sialylation level, and that 
ChEPO-SG showed increased β1,4 and β1,6 branching at the trimannosyl core of the N-
glycans. Then, recombinant human EPO was purified from each cell line and subjected to 
lectin blot and HPLC analysis. Both methods proved that EPO from ChEPO-S had a 
notably higher content of terminal α2,6-sialic acid, compared to that produced by ChEPO 
cells. Furthermore, EPO purified from ChEPO-SG, with a larger extent of β1,4 and β1,6 
branching, exhibited an even higher level of sialylation than ChEPO-S. 
This study for the first time investigates and quantifies the effect of simultaneous 
overexpression of ST6GAL1, GNTIV and GNTV on enhancing the N-glycosylation 
complexity and terminal sialylation of human EPO produced in CHO cells. This strategy 
can be utilized to improve the glycosylation of a variety of other recombinant therapeutic 
glycoproteins in a robust manner. Moreover, our study contributes insights into future 
glycoengineering of other glycosyltransferases within the N-glycosylation pathway, in 
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order to expand the complexity and improve sialylation of recombinant proteins of 





Chapter 5: Future Work 
5.1 Mass Spectrometry to Analyze Recombinant Human EPO N-glycan Structures 
In this study, results from lectin blot and HPLC demonstrated that transfection of 
ST6GAL1 into recombinant EPO producing CHO cells introduced α2,6-linked sialylation 
and elevated the overall sialic acid contents. Additional simultaneous transfection of 
GNTIV and GNTV improved the size and extent of antennarity of the N-glycan, creating 
more sites available for sialic acid. However, the specific N-glycan structures on 
recombinant human EPO from each cell line need to be further elucidated by mass 
spectrometry. 
For glycomic analysis, N-glycans need to be cleaved from purified recombinant 
human EPO as previously described, and then subjected to the mass spectrometer [59]. It 
will be very beneficial to figure out the number of sialic acid residues per N-glycan as 
well as the percentages of bi-, tri-, and tetra-branched N-glycan structures of EPO 
produced by various CHO cell lines, as such we will have a deeper understanding of the 
impact of ST6GAL1, GNTIV and GNTV on N-glycosylation patterns, and we can better 
tailor the complex N-glycan structures on therapeutic glycoproteins in future. 
5.2 Further Improvement of Sialylation by Nucleotide Sugar Precursor Feeding 
As previously mentioned, strategies affecting the level of glycosylation include 
alteration of the activity of glycosyltransferases for sugar residue transfer, the action of 
glycosidases on the glycan degradation, and the amount of nucleotide sugar substrate 
[30]. In this study, three glycosyltransferases, ST6GAL1, GNTIV and GNTV were 
transfected into CHO cells and therefore increased the protein sialylation level. To further 
elevate the sialic acid content, future work can be providing CHO cells nucleotide sugar 
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substrate. Specifically, a sufficient amount of the nucleotide sugar precursor sialic acid 
and CMP-sialic acid is essential for the sialylation process [60]. However, due to the low 
cell membrane permeability, it is not helpful to feed CHO cells sialic acid or CMP-sialic 
acid [61]. Hence, feeding N-acetylmannosamine, ManNAc, the direct precursor for 
intracellular synthesis of sialic acid with high cell membrane permeability, became an 
optimal solution (See Figure 4). Gu and Wang fed 20 mM ManNAc to CHO cells 
expressing recombinant INF- γ, and successfully increased the CMP-sialic acid level by 
30 times and protein sialylation level by 15% [61]. Similarly, we will feed ManNAc or its 
derivatives to ChEPO, ChEPO-S and ChEPO-SG cells, and observe its impact on 
sialylation level of intracellular proteins and purified recombinant EPO. 
5.3 Enhancement of Sialylation by Targeted Gene Silencing 
In addition to nucleotide sugar precursor feeding, the sialylation level of 
recombinant human EPO can be enhanced by treating cells with short interfering RNA 
(siRNA) and short-hairpin RNA (shRNA) in order to reduce the expression of sialidase 
genes, as sialidases catalyze the removal of terminal sialic acids from the glycoprotein 
[62]. Four sialidases (Neu1-4) have been found at different locations in the human, 
mouse, and rat cells, and their functions varied from each other possibly due to different 
subcellular locations and substrate specificity [63]. Ngantung et al. used the RNAi 
technique to decrease the expression of cytosolic sialidase (Neu2) in CHO cells 
producing recombinant human INF- γ. They found that the sialidase activity was reduced 
by about 60% and that CHO cells successfully retained the full sialic acid content of the 
glycoprotein [64]. Similarly, Zhang et al. knocked down the expression of lysosomal 
sialidase (Neu1) and plasma membrane sialidase (Neu3), and observed an increased 
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sialylation level by 33% and 26%, respectively. Thus, to further enhance the sialylation 
of recombinant human EPO produced by ChEPO-S and ChEPO-SG cells, we will knock 
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